Diagnostic screening biomarker for stoneformers

WO2024215637A8PCT designated stage expired Publication Date: 2024-11-28THE UAB RESEARCH FOUNDATION INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/023669
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-08
Filing Date
2024-04-09
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current methods lack a practical, cost-effective, and safe diagnostic screening tool to identify individuals with AGT deficiency who would benefit from specific drugs for calcium oxalate stone disease, particularly in the heterogeneous stoneforming population, and cannot differentiate between dietary and endogenous oxalate sources.

Method used

A diagnostic tool using carbon-13 labeled glycolate breath test to assess the conversion of glycolate to CO2, allowing for the characterization of AGT deficiency and determining suitability for targeted drug therapies.

Benefits of technology

Enables rapid and safe characterization of stoneformers with AGT deficiency, identifying candidates for specific treatments and potentially benefiting chronic kidney disease patients by differentiating endogenous oxalate sources, thus improving treatment efficacy and reducing the burden of low-oxalate diets.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024023669_28112024_PF_FP_ABST
    Figure US2024023669_28112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein is a diagnostic / screening / biomarker tool that can rapidly and safely implemented in clinics to characterize those stoneformers with alanine : glyoxylate aminotransferase (AGT) deficiency (genetically or functionally). Also disclosed are methods of diagnosing and treating calcium oxalate (CaOx) stone disease in subjects with detected AGT deficiency.
Need to check novelty before this filing date? Find Prior Art

Description

DIAGNOSTIC SCREENING BIOMARKER FOR STONEFORMERSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims benefit of U.S. Provisional Application No. 63 / 495,894, filed April 13, 2023, and U.S. Provisional Application No. 63 / 597,189, filed November s, 2023, which are hereby incorporated herein by reference in their entireties.BACKGROUND OF THE INVENTION

[0002] Calcium oxalate (CaOx) stone disease generates billions of dollars in healthcare costs including large economic losses due to decreased work productivity, and negatively impacts quality of life. More than ten percent of the population may now experience a stone event at least once in their lifetime and that figure is increasing. Although stone removing treatments have advanced over the last few decades, our knowledge of how stones form and how to prevent them has not kept pace. It remains evident that the concentrations of calcium, oxalate and citrate in urine are critical determinants of stone formation. Drugs are available to alter calcium and citrate excretion and are among the few proven therapies to limit calcium oxalate stone disease; for example, thiazides are prescribed to decrease calcium excretion and citrate salts are prescribed to increase citrate excretion. The main approach for lowering oxalate excretion in this cohort has been maintenance of normal calcium intake (1000 - 1200 mg / day in adults), and low oxalate intake to limit intestinal oxalate absorption. However, this does not address the contribution of endogenous oxalate synthesis to the urinary oxalate pool, which is estimated to be 50%. Recent drugs have proven to be effective in lowering urinary oxalate in a rare genetic condition, primary hyperoxaluria. Despite this advancement, there has been no creation of a diagnostic test, screening tool, or biomarker to determine if there are individuals in the highly heterogenous stoneforming population that may benefit from these drugs that are directed at endogenous oxalate. The only tools currently available are placing individuals on highly controlled low oxalate diets and collecting 24 hour urines, essentially eliminating the dietary oxalate source and evaluating the urinary oxalate as endogenous. This is a huge undertaking and is not practical in the real world. Further it does not differentiate the sources of endogenous oxalate and will not determine those who may be best to respond to the current treatments. A better, easier, cost effective, and safe approach is needed to characterize CaOx stoneformers and determine those that could respond to current treatments. Such a test could prove beneficial not just in CaOx kidney stones, but perhaps those patients with chronic kidneydisease given the recent study demonstrating that urinary oxalate excretion is positively correlated to chronic kidney disease (CKD) progression.SUMMARY OF THE INVENTION

[0003] Disclosed herein is a diagnostic / screening / biomarker tool that can rapidly and safely implemented in clinics to characterize those stoneformers with AGT deficiency (genetically or functionally). These individuals would be the exact candidates that would benefit from the very specific drugs that are being studied or already have been studied and have FDA approval (in PH1).

[0004] This disclosed methods can also be used to confirm the diagnosis in patients with suspected primary hyperoxaluria type 1 who have been genetically tested and carry variants of unknown significance.

[0005] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.BRIEF DESCRIPTION OF FIGURES

[0006] FIG. 1. Metabolic pathways of endogenous oxalate synthesis. AGT: alanine:glyoxylate aminotransferase, LDH: lactate dehydrogenase, GO: glyoxylate oxidase, GR: glyoxylate reductase, HOGA1 : 4-hydroxy-2-oxoglutarate aldolase, HYPDH: hydroxyproline dehydrogenase. DAO: D-amino oxidase. Vitamin C to oxalate is non enzymatic. Green arrows: potential therapeutic targets. %: contribution of precursors in healthy human controls.

[0007] FIGs 2A to 2C. Assessment of contribution glycolate to EOS in healthy subjects. Plasma (blue and magenta circles) and Urine (black triangles) excess mole percent enrichment (MPE) are used for the calculation of % contribution to EOS (bolded in box inserts), representative data for n=3 subjects. (A): Glycolate contribution by constant infusion, (B) single oral dose and (C) single intravenous dose of13C2-Glycolate. Steady-state is achieved at 4 hr in (A). For (B and C) the short half-life of glycolate (90 min) allows whole capture of the area under the curve in 6h for plasma and 24h for urine and thus accurate calculation of contribution. The infusion and single dose methods for contribution of glycolate give comparable results (3 vs 5% n=7 subjects, p=0.13) in line with [Garrelfs, JASN 2021],

[0008] FIG 3. Assessment of AGT activity by breath13CO2in HV. A single oral dose of13C2-Glycolate (33 & 150 mg) is metabolized to glyoxylate by GO, then glycine by AGT and subsequently to13CO2, with a peak at 40 minutes. Triangles, hourly % and circles cumulative %

[0009] FIG 4. Decreased conversion of an oral dose of13C2-glycolate to13CO2in patients with primary hyperoxaluria type 1. The cumulative conversion of an oral dose of13C2- glycolate to13CO2was tested in 14 healthy volunteers (“HV”, 7 males, 7 females, median and interquartile range shown), in 2 patients with severe forms of primary hyperoxaluria type 1 (no functional AGT) and treated with the GO RNAi therapy, Lumasiran (PH1 group A, only median shown), and in an untreated patient with primary hyperoxaluria type 1 and a mutation associated with residual AGT activity (PH1 group B). The one patient with a milder form of PH1 and untreated shows a lower conversion of glycolate to CO2compared with healthy non kidneystone forming volunteers. The data demonstrate the utility of the 13-CO2breath test following13C2-glycolate oral dosing in assessing the functionality of the GO-AGT axis.DETAILED DESCRIPTION

[0010] Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

[0011] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

[0012] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.

[0013] All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. Thecitation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be independently confirmed.

[0014] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.

[0015] Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of chemistry, biology, and the like, which are within the skill of the art.

[0016] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to perform the methods and use the probes disclosed and claimed herein. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C, and pressure is at or near atmospheric. Standard temperature and pressure are defined as 20 °C and 1 atmosphere.

[0017] Before the embodiments of the present disclosure are described in detail, it is to be understood that, unless otherwise indicated, the present disclosure is not limited to particular materials, reagents, reaction materials, manufacturing processes, or the like, as such can vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting. It is also possible in the present disclosure that steps can be executed in different sequence where this is logically possible.Definitions

[0018] It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.

[0019] The term “subject” refers to any individual who is the target of administration or treatment. The subject can be a vertebrate, for example, a mammal. Thus, the subject can be a human or veterinary patient. The term “patient” refers to a subject under the treatment of a clinician, e.g., physician.

[0020] The term “therapeutically effective” refers to the amount of the composition used is of sufficient quantity to ameliorate one or more causes or symptoms of a disease or disorder. Such amelioration only requires a reduction or alteration, not necessarily elimination.

[0021] The term “pharmaceutically acceptable” refers to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit / risk ratio.

[0022] The term “carrier” means a compound, composition, substance, or structure that, when in combination with a compound or composition, aids or facilitates preparation, storage, administration, delivery, effectiveness, selectivity, or any other feature of the compound or composition for its intended use or purpose. For example, a carrier can be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject.

[0023] The term “sample from a subject” refers to a tissue (e.g., tissue biopsy), organ, cell (including a cell maintained in culture), cell lysate (or lysate fraction), biomolecule derived from a cell or cellular material (e.g. a polypeptide or nucleic acid), or body fluid from a subject. Non-limiting examples of body fluids include blood, urine, plasma, serum, tears, lymph, bile, cerebrospinal fluid, interstitial fluid, aqueous or vitreous humor, colostrum, sputum, amniotic fluid, saliva, anal and vaginal secretions, perspiration, semen, transudate, exudate, and synovial fluid.

[0024] The term “treatment” refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.

[0025] The term “prevent” refers to a treatment that forestalls or slows the onset of a disease or condition or reduced the severity of the disease or condition. Thus, if a treatment can treat a disease in a subject having symptoms of the disease, it can also prevent that disease in a subject who has yet to suffer some or all of the symptoms.Isotopes

[0026] Disclosed herein are carbon-13 isotopes of glycolate, hydroxyproline, glyoxylate, glycine, pyruvate, and / or lactate in a pharmaceutically acceptable carrier for use in the disclosed methods. Pharmaceutical carriers suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of administration.

[0027] The isotopes are, in one embodiment, formulated into suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administration or in sterile solutions or suspensions for parenteral administration.

[0028] Liquid pharmaceutically acceptable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing isotopes as defined above in a carrier, such as, for example, water, to thereby form a solution or suspension.

[0029] Oral pharmaceutical dosage forms are either solid, gel or liquid. The solid dosage forms are tablets, capsules, granules, and bulk powders. Types of oral tablets include compressed, chewable lozenges and tablets which may be enteric-coated, sugar-coated or film- coated. Capsules may be hard or soft gelatin capsules, while granules and powders may be provided in non-effervescent or effervescent form with the combination of other ingredients known to those skilled in the art.Breath Test

[0030] An analytical assay is described that is based on the use of non-radioactive13C. Labeled expired13CO2is measured in the present assay. The test protocol is as follows: after an overnight fast, an oral dose of13C labeled glycolate, hydroxyproline, glyoxylate, glycine, pyruvate, or lactate is administered. Suitable doses range from 5 to 500 mg, such as 5 to 100 mg, 10 to 100, 10 to 200, 10 to 500, 20 to 100, 20 to 500, 50 to 100, 50 to 500, 100 to 500; including 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500). Breath samples can be collected before the dose and then 1 to 24,such as 1 to 10, 10 to 24, 5 to 12, 10 to 24 hours, including 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24 hours, after isotope ingestion. Levels of13CO2in expired air will be measured.

[0031] The best known means for CO2isotope measurements is isotope ratio mass spectrometry (I RMS). Non-dispersive infrared spectroscopy (NDIRS) analysis and analysis methods known in the art may be employed.

[0032] A laser-based, temperature insensitive, CO2isotope ratio measurement device is described in US 2015 / 0219553, which is incorporated by reference in its entirety for the teaching of these devices and method of use. For example, the method can involve introducing gas into a gas sample chamber; directing light into the sample chamber from a laser light source, the laser light source being capable of accessing one or more of the wavelength pairs 2054.37 and 2052.42; 2054.96 and 2051.67; and 2760.53 and 2760.08 nanometers; and with a detector detecting the laser light energy after passage through the sample chamber. A processor can interpret or present the signals received by the detector. The laser light source scans the pair of wavelengths using wavelength modulation spectroscopy. The laser light source can comprise a single laser emitter and is a vertical cavity surface emitting laser. Alternatively, the laser light source can comprise a pair of laser emitters.

[0033] A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.EXAMPLESExample 1:

[0034] In Figure 1 , there is the depiction of the known endogenous oxalate pathway in hepatocytes with the multiple enzymes involved. AGT is mutated in Primary Hyperoxaluria Type 1. GR is mutated in Primary Hyperoxaluria Type 2. HOGA is mutated in Primary Hyperoxaluria Type 3. Drugs have been or are in development targeting the enzymes with the green arrows. In figure 1 , we have demonstrated that glycine can convert to CO2. Using the novelty of a cold isotope carbon 13 by oral (or IV) load of any precursor, but in this specific invention glycolate, and measuring the carbon 13 CO2, we can characterize those individuals that have a genetic or functional deficiency in AGT and thus would benefit from the current drugs or those in development. In those individuals with low conversion of C13 glycolate to C13 CO2, we would then know they have this functional or genetic mutation. Recent evidence suggest that evenfatty liver, a highly prevalent condition and one associated with stone disease, may lead to deficiency in AGT. Further there is evidence that these individuals may have elevated urinary oxalate, and thus increased stone risk.

[0035] Figure 2 demonstrates work in our lab to understand the pharmacodynamics properties of oral and intravenous infusion or bolus of carbon 13 glycolate. We have an understanding and demonstrated the ability to measure carbon 13 in plasma and urine. In Figure 3, we demonstrate our ability after carbon 13 oral glycolate load to measure and quantify the carbon 13 CO2that is produced in a human. We have done this at 2 different doses demonstrating consistent percent recovery.

[0036] This data clearly shows that we have a diagnostic / screening / biomarker tool that can rapidly and safely implemented in clinics to characterize those stoneformers with AGT deficiency (genetically or functionally). These individuals would be the exact candidates that would benefit from the very specific drugs that are being studied or already have been studied and have FDA approval (in PH1). This is to our knowledge the first available test that could “phenotype” the heterogenous stoneforming population and actually create a subset of individuals that could be successfully treated.

[0037] We suspect that this would have immediate implications on the life cycle and clinical trial design of currently approved drugs, Lumasiran and Nedosiran, and also the multiple companies with various stage clinical trials in primary hyperoxaluria (BridgeBio, Chinook, Arbor, Intellia, Biomarin). This may also serve as a monitoring tool for those individuals where lifestyle modifications or other interventions are implemented to restore AGT activity, including pyridoxine therapy in PH1. Further, it can be used in certain situations (those with some residual AGT activity) to assess target-drug engagement and effects and determine if alterations in dosing are needed.

[0038] In the scenario of a PH2 individual, there would be excess CO2carbon 13. This test can help understand and clarify the genotype-phenotype variability in this population. It similarly can categorize those with a functional deficiency in glyoxylate reductase in the stoneforming population and benefit from drug therapy.

[0039] Figure 4 shows decreased conversion of an oral dose of13CO2-glycolate to13CO2in patients with primary hyperoxaluria type 1. The cumulative conversion of an oral dose of13C2- glycolate to13CO2was tested in 14 healthy volunteers (“HV”, 7 males, 7 females, median and interquartile range shown), in 2 patients with severe forms of primary hyperoxaluria type 1 (no functional AGT) and on Lumasiran treatment (PH1 group A, only median shown), and in anuntreated patient with primary hyperoxaluria type 1 and a mutation associated with residual AGT activity (PH1 group B). The one patient with a milder form of PH1 and untreated shows a lower conversion of glycolate to CO2compared with healthy non kidney-stone forming volunteers. The data demonstrate the utility of the 13-CO2breath test following13C2-glycolate oral dosing in assessing the functionality of the GO-AGT axis.

[0040] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.

[0041] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

CLAIMS1. A method for diagnosing deficient AGT, HOGA1 or GRHPR in calcium oxalate (CaOx) stone disease, the method comprising:(a) administering to the subject a carbon-13 isotope of glycolate, carbon-13 isotope of hydroxyproline, carbon-13 isotope of glyoxylate, carbon-13 glycine, carbon-13 pyruvate or carbon-13 isotope of lactate; and(b) measuring carbon-13 CO2in the breath of the subject by mass spectrometry based assays to calculate alanine:glyoxylate aminotransferase (AGT) activity, 4-hydroxy-2- oxoglutarate aldolase (HOGA1) activity, glyoxylate reductase activity and alanine:glyoxylate aminotransferase (AGT) activity, glycine cleavage system and D-amino oxidase activity, lactate dehydrogenase (LDH) activity, or lactate dehydrogenase (LDH) activity in the subject, respectively; wherein deficient AGT, HOGA1 , or GRHPR activity is an indication of CaOx stone disease.

2. The method of claim 1 , wherein the spectrometry based assay is gas chromatography mass spectrometry.

3. The method of claim 1 , wherein the subject is suspected of having primary hyperoxaluria (PH) and / or carries a genetic variant of unknown significance.

4. A method for treating calcium oxalate (CaOx) stone disease or chronic kidney disease (CKD) in a subject,(a) administering to the subject a cold carbon-13 isotope of glycolate, carbon-13 isotope of hydroxyproline, carbon-13 isotope of glyoxylate, carbon-13 glycine, carbon-13 pyruvate, or carbon-13 isotope of lactate;(b) measuring carbon-13 CO2in the breath of the subject to calculate alanine:glyoxylate aminotransferase (AGT) activity, 4-hydroxy-2-oxoglutarate aldolase (HOGA1) activity, glyoxylate reductase activity and alanine:glyoxylate aminotransferase (AGT) activity, glycine cleavage system and D-amino oxidase activity, lactate dehydrogenase (LDH) activity, or lactate dehydrogenase (LDH) activity in the subject, respectively;(c) detecting deficient AGT, HOGA1 , or LDH activity in the subject; and(d) administering to the subject an effective amount of an agent that that lowers endogenous oxalate production.

5. The method of claim 3, wherein the agent comprises lumasiran, BBP-711 , BMN-255, nedosiran, CHK-336, stiripentol.

6. The method of claim 3, wherein the agent comprises an agent that inhibits enzymes involved in oxalate synthesis.

7. The method of claim 5, wherein the agent comprises hydroxyproline dehydrogenase, glycolate oxidase, lactate dehydrogenase, D-amino acid oxidase and xanthine oxidase.

8. The method of any one of claims 1 to 6, wherein the carbon-13 isotope of glycolate, carbon-13 isotope of hydroxyproline, carbon-13 isotope of glyoxylate, carbon-13 glycine, carbon-13 pyruvate or carbon-13 isotope of lactate is administered to the subject orally or intravenously.

9. The method of claim 7, wherein the carbon-13 isotope of glycolate, carbon-13 isotope of hydroxyproline, carbon-13 isotope of glyoxylate, carbon-13 glycine, carbon-13 pyruvate, carbon- 13 isotope of lactate, or any combination thereof, is administered at a dosage less than 50mg.

10. The method of claim 8, wherein the carbon-13 isotope of glycolate, carbon-13 isotope of hydroxyproline, carbon-13 isotope of glyoxylate, carbon-13 glycine, carbon-13 pyruvate, carbon- 13 isotope of lactate, or any combination thereof, is administered at a dosage from 5 to 500mg.11 . The method of claim 2 or 3, wherein the agent inhibits glycolate oxidase (GO) enzyme expression or activity.

12. The method of claim 4, wherein the agent is lumasiran, BBP-711 , or BMN-255.

13. The method of claim 2 or 3, wherein the agent inhibits lactate dehydrogenase (LDH) expression or activity.

14. The method of claim 6, wherein the agent is nedosiran, CHK-336, or stiripentol.

15. The method of clam 3, wherein the agent inhibits hydroxyproline dehydrogenase(HYPDH) expression or activity.

16. The method of any one of claims 2 to 8, further comprising repeating steps (a) to (c) to monitor AGT activity over time.

17. The method of any one of claims 1 to 15, wherein the carbon-13 isotope of glycolate is13C2-glycolate or13Ci-glycolate.

18. The method of any one of claims 1 to 15, wherein the carbon- 13 isotope of hydroxyproline is13Ci-hydroxyproline,13C2-hydroxyproline,13C3-hydroxyproline,13C4- hydroxyproline,13C5-hydroxyproline.

19. The method of any one of claims 1 to 15, wherein the carbon- 13 isotope of lactate is13Ci-lactate,13C2-lactate or13C3-lactate.

20. The method of any one of claims 1 to 15, wherein the carbon- 13 isotope of glyoxylate is13C2-glyoxylate or13Ci-glyoxylate.

21. The method of any one of claims 1 to 15, wherein the carbon-13 isotope of glycine is13C2-glycine or13Ci-glycine.

22. The method of any one of claims 1 to 15, wherein the carbon-13 isotope of pyruvate is13C3-pyruvate,13C2-pyruvate or13Ci -pyruvate.

23. A method for diagnosing a primary hyperoxaluria type II (PH2) disease in a subject, the method comprising assaying a blood cell from the subject for glyoxylate reductase (GR) and / or D-glycerate dehydrogenase (DGDH) activity, wherein a decrease in GR and / or DGDH activity is an indication that the subject has glyoxylate red uctase / hydroxy pyruvate reductase (GRHPR) deficiency.

24. The method of claim 22, wherein the blood cell is a blood mononuclear cell (BMC) and / or red blood cells.

25. The method of claim 22 or 23, further comprising treating the subject for PH2 disease.

26. The method of claim 24, comprising treating the subject with an agent that , decreases HYPDH, GO and / or LDH activity.